DE602007012681D1 - Verfahren zur produktion von antikörpern in immundefizienten tieren, denen humane fötale leberstammzellen injiziert wurden - Google Patents

Verfahren zur produktion von antikörpern in immundefizienten tieren, denen humane fötale leberstammzellen injiziert wurden

Info

Publication number
DE602007012681D1
DE602007012681D1 DE602007012681T DE602007012681T DE602007012681D1 DE 602007012681 D1 DE602007012681 D1 DE 602007012681D1 DE 602007012681 T DE602007012681 T DE 602007012681T DE 602007012681 T DE602007012681 T DE 602007012681T DE 602007012681 D1 DE602007012681 D1 DE 602007012681D1
Authority
DE
Germany
Prior art keywords
fötale
ficients
humane
antibodies
immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007012681T
Other languages
English (en)
Inventor
Alexander Lifke
Valeria Lifke
Bernd Mueller-Beckmann
Tobias Schnitzer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37451065&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602007012681(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of DE602007012681D1 publication Critical patent/DE602007012681D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE602007012681T 2006-05-11 2007-05-09 Verfahren zur produktion von antikörpern in immundefizienten tieren, denen humane fötale leberstammzellen injiziert wurden Active DE602007012681D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06009703 2006-05-11
PCT/EP2007/004085 WO2007131676A1 (en) 2006-05-11 2007-05-09 Method for the production of antibodies in immunodeficient animal injected with human fetal liver stem cells

Publications (1)

Publication Number Publication Date
DE602007012681D1 true DE602007012681D1 (de) 2011-04-07

Family

ID=37451065

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007012681T Active DE602007012681D1 (de) 2006-05-11 2007-05-09 Verfahren zur produktion von antikörpern in immundefizienten tieren, denen humane fötale leberstammzellen injiziert wurden

Country Status (17)

Country Link
US (4) US20070266448A1 (de)
EP (1) EP2016099B1 (de)
JP (1) JP4865035B2 (de)
KR (1) KR20080113279A (de)
CN (3) CN101400702A (de)
AR (1) AR060996A1 (de)
AT (1) ATE499437T1 (de)
AU (1) AU2007251856A1 (de)
BR (1) BRPI0711807A2 (de)
CA (1) CA2650109C (de)
CL (1) CL2007001346A1 (de)
DE (1) DE602007012681D1 (de)
ES (1) ES2359585T3 (de)
IL (1) IL193691A0 (de)
MX (1) MX2008013513A (de)
TW (1) TW200813086A (de)
WO (1) WO2007131676A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070269412A1 (en) * 2003-12-02 2007-11-22 Celavie Biosciences, Llc Pluripotent cells
NZ583605A (en) 2007-08-29 2012-10-26 Sanofi Aventis Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
US20100209399A1 (en) * 2009-02-13 2010-08-19 Celavie Biosciences, Llc Brain-derived stem cells for repair of musculoskeletal system in vertebrate subjects
US8778677B2 (en) * 2009-06-10 2014-07-15 BTS Research International PTY. Ltd. Methods of generating hybrid/chimeric cells, and uses thereof
CN101696396A (zh) * 2009-10-27 2010-04-21 中国人民解放军军事医学科学院卫生学环境医学研究所 乙型肝炎病毒体外感染模型的构建方法及应用
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
EP3183001A4 (de) * 2014-08-22 2018-01-17 Sorrento Therapeutics, Inc. Antigenbindende proteine zur bindung von cxcr5
EP3889175A1 (de) 2016-05-02 2021-10-06 F. Hoffmann-La Roche AG Der contorsbody - ein einkettiger targetbinder
KR20190038613A (ko) * 2016-08-11 2019-04-08 더 잭슨 래보라토리 유전자 변형된 면역결핍 비-인간 동물에서의 개선된 인간 적혈구 생존에 관한 방법 및 조성물
JP6931058B2 (ja) 2016-12-21 2021-09-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗体のインビトロ糖鎖工学における酵素の再使用
EP3559249A1 (de) 2016-12-21 2019-10-30 H. Hoffnabb-La Roche Ag Verfahren zum in-vitro-glycoengineering von antikörpern
MX2019006266A (es) 2016-12-21 2019-08-21 Hoffmann La Roche Glucomanipulacion in vitro de anticuerpos.
EP3704150A1 (de) 2017-11-01 2020-09-09 F. Hoffmann-La Roche AG Compbody ein multivalentes zielbindemittel
BR112020008031A2 (pt) 2017-11-01 2020-10-27 F. Hoffmann-La Roche Ag anticorpo multiespecíficos, método para a preparação do anticorpo multiespecífico, conjunto de ácidos nucleicos, vetor de expressão, célula hospedeira e composição farmacêutica

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
EP0322240B1 (de) * 1987-12-23 1995-03-01 The Board Of Trustees Of The Leland Stanford Junior University Schimäre immunkompromittierende Säugetiere und ihre Verwendung
US5434341A (en) * 1989-08-17 1995-07-18 Systemix, Inc. Xenogeneic lymph node in mammary fat pad
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US6455678B1 (en) * 1996-04-26 2002-09-24 Amcell Corporation Human hematopoietic stem and progenitor cell antigen
DE69841322D1 (de) * 1997-10-06 2010-01-07 Novartis Vaccines & Diagnostic Hepatitis c rezeptorprotein cd81
US7039115B1 (en) * 2000-09-20 2006-05-02 General Instrument Corporation Processor allocation for channels in a video multi-processor system
JP2003225089A (ja) 2002-02-04 2003-08-12 National Institute Of Agrobiological Sciences ブタｒａｇ−１遺伝子およびその利用
EP1474682A4 (de) 2002-02-11 2005-10-12 Alexion Pharma Inc Produktion von menschlichen antikörpern in immundefizienten, nicht-menschlichen säugerwirten
CN1835679A (zh) * 2003-06-16 2006-09-20 国立大学法人九州大学 人源免疫活性细胞的制备方法

Also Published As

Publication number Publication date
IL193691A0 (en) 2011-08-01
CA2650109A1 (en) 2007-11-22
EP2016099B1 (de) 2011-02-23
MX2008013513A (es) 2008-10-28
TW200813086A (en) 2008-03-16
CN107090033A (zh) 2017-08-25
CL2007001346A1 (es) 2008-03-14
ATE499437T1 (de) 2011-03-15
US20100105073A1 (en) 2010-04-29
US20120195903A1 (en) 2012-08-02
KR20080113279A (ko) 2008-12-29
US20130189270A1 (en) 2013-07-25
CN102532318A (zh) 2012-07-04
US20070266448A1 (en) 2007-11-15
AR060996A1 (es) 2008-07-30
JP4865035B2 (ja) 2012-02-01
WO2007131676A1 (en) 2007-11-22
CN101400702A (zh) 2009-04-01
US8884096B2 (en) 2014-11-11
BRPI0711807A2 (pt) 2011-12-06
ES2359585T3 (es) 2011-05-24
JP2009536631A (ja) 2009-10-15
EP2016099A1 (de) 2009-01-21
CA2650109C (en) 2017-11-07
AU2007251856A1 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
DE602007012681D1 (de) Verfahren zur produktion von antikörpern in immundefizienten tieren, denen humane fötale leberstammzellen injiziert wurden
DE502006001614D1 (de) Verfahren zur herstellung von 1-alkyl-3-phenyluracilen
ATE527887T1 (de) Verfahren zur herstellung von teeprodukten
ATE455105T1 (de) Verfahren zur herstellung von difluormethylpyrazolylcarboxylaten
ATE471083T1 (de) Verfahren zur herstellung von müsliriegeln mit verbesserter konsistenz
ATE516816T1 (de) Verfahren zur herstellung von impfstoffen
DE602006015090D1 (de) Verfahren zur herstellung von gezielt durchlässigen laminaten
ATE472564T1 (de) Verfahren zur verringerung von gelen in polyolefinen
DE602007009096D1 (de) Verfahren zur herstellung von benzopyran-2-olderivaten
DE502005010038D1 (de) Verfahren zur herstellung von 3-pentennitril
DE602007001585D1 (de) Verfahren zur herstellung von kunstlatex
ATE533747T1 (de) Verfahren zur herstellung von tetrahydrochinolinderivaten
ATE399157T1 (de) Verfahren zur herstellung von telmisartan
DE112010003301A5 (de) Spritzgiessverfahren zur herstellung von bauteilen
ATE548345T1 (de) Verfahren zur herstellung von agomelatin
ATE518847T1 (de) Verfahren zur herstellung von betamimetika
ATE542808T1 (de) Verfahren zur herstellung von epichlorydrin aus glyzerin
ATE546436T1 (de) Verfahren zur herstellung von 2-amino-5- cyanobenzoesäurederivaten
ATE444303T1 (de) Verfahren zur herstellung von ferrisuccinylcasein
DE602008006766D1 (de) Verfahren zur herstellung von würzwürfeln
ATE554088T1 (de) Verfahren zur herstellung von pyridoä2,1- aüisochinolinderivaten
DE602006004185D1 (de) Verfahren zur herstellung geschützter amidine
ATE510816T1 (de) Verfahren zur herstellung von agomelatin
DE502006002029D1 (de) Verfahren zur herstellung von polyetheraminen
DE602007011324D1 (de) Verfahren zur herstellung von 2-substituierten 5-(1-alkylthio)alkylpyridinen